Strategic funding Verily Health has a robust funding base with total funding of 3.8B and a revenue range in the billions, indicating strong financial capacity to invest in large-scale data platforms, AI initiatives, and enterprise partnerships.

Enterprise partnerships Active and expanding collaborations with global tech and health players including Alphabet, Samsung, Salesforce, UCHealth, and academic institutions signal opportunity to position integrated AI-powered precision health solutions across large healthcare networks and software ecosystems.

Global expansion Recent and planned expansions into Singapore and partnerships across Europe and the US suggest readiness to scale deployments, support international regulatory compliance, and tailor solutions to diverse healthcare markets.

Clinical AI readiness Verily’s focus on AI-enabled precision health and a platform designed to make data AI-ready across care, research, and public health aligns with opportunities to supply data integration, governance, and analytics capabilities to hospitals and life sciences customers.

Consumer and device convergence Movements such as Verily Me and collaborations with consumer devices (Galaxy Watch) create avenues to offer wearables data integration, remote monitoring capabilities, and biomarker-driven trials for payer, provider, and pharmaceutical customers.